Clinical Characteristics of Myeloproliferative Neoplasms in Patients with <i>DDX41</i>MT Germline Predisposition Syndrome
Yael Kusne(WinnMed), Mrinal M. Patnaik(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Animesh Pardanani(Mayo Clinic), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), James M. Foran(Memorial Sloan Kettering Cancer Center), Timothy M. Chlon(Cincinnati Children's Hospital Medical Center), Jeanne Palmer(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Christy M. Finke(Mayo Clinic), Talha Badar(Mayo Clinic in Florida), Alejandro Tiana Ferrer(Mayo Clinic in Arizona), Mark R. Litzow(Mayo Clinic in Arizona), Naseema Gangat(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 1
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k